3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Hyperphagia
8
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms
2
Malnutrition
2
Postoperative Complications
1
Nutritional Support
1
Nasopharyngeal Carcinoma
1
Head and Neck Neoplasms
1
Disease Progression
1
Digestive System Neoplasms
1
Deglutition Disorders
1
Interventions
Gemcitabine
7
Leucovorin
6
Irinotecan
6
Fluorouracil
6
130-nm albumin-bound paclitaxel
6
Albumin-Bound Paclitaxel
5
napabucasin
4
Capecitabine
4
Paclitaxel
3
Oxaliplatin
3
Ocoxin
3
Bevacizumab
3
pembrolizumab
2
entinostat
2
Sorafenib
2
Imatinib Mesylate
2
Everolimus
2
Cyclophosphamide
2
Cisplatin
2
Cetuximab
2
5,10-methylenetetrahydrofolic acid
2
tislelizumab
1
spartalizumab
1
pralsetinib
1
palbociclib
1
irinotecan sucrosofate
1
halofantrine
1
guadecitabine
1
fludarabine
1
ficlatuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Digestive System Neoplasms
×
Parenteral Nutrition
×
Clear all
NCT03115957
2020-09-29
PNASIT
Jinling Hospital, China
Phase NA
Completed
230 enrolled